The key study results were:
- Treatment with Tarceva in patients with advanced NSCLC resulted in
significantly longer survival compared to placebo, a 42.5% improvement
(6.7 months vs. 4.7 months).
- 31% of patients receiving Tarceva were alive at one year compared to
22% in the placebo arm.
- Patients receiving Tarceva had stability or control of their lung
cancer-related symptoms such as cough, shortness of breath and pain,
for significantly longer.
- Patients also had a superior quality of life and improved physical
function compared to those on placebo.
- The benefits of Tarceva were shown in a broad spectrum of patients
Tarceva is the first and only EGFR oral targeted agent with proven and significant survival and symptom benefit in a broad range of patients with advanced lung and pancreatic cancer. Currently most lung and pancreatic cancer patients are treated wholly with chemotherapy which can be very debilitating due to its toxic nature. Tarceva works differently than chemotherapy by specifically targeting tumor cells, and avoids most of the typical side-effects of chemotherapy.
Tarceva has been approved in the European Union since September 2005 and in the US since November 2004 for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. Furthermore, Tarceva, in combination with chemotherapy, is the first treatment in over a decade to have shown a significant survival benefit in treating patients with pancreatic cancer. It is approved in the US, in combination with gemcitabine, for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer and in the EU for treatment of metastatic pancreatic cancer. Since its initial launch four years ago, Tarceva has been used to treat more than 200,000 patients and has been approved in 85 countries worldwide.
Roche in Oncology
The Roche Group, including its members Genentech in the United States and Chugai in Japan, is the world's leading provider of cancer care products, including anti-cancer treatments, supportive care products and diagnostics. Its oncology business includes an unprecedented five products proven to provide survival benefit in different major tumor indications: Avastin, Herceptin, and Xeloda in advanced-stage breast cancer, Herceptin in early-stage HER2-positive breast cancer, MabThera in non-Hodgkin's lymphoma, Avastin and Xeloda in colorectal cancer, Avastin and Tarceva in NSCLC and Tarceva in pancreatic cancer. For further information on Roche please go to http://www.roche.com.